|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current medical treatment of estrogen receptor-positive breast cancer显示文摘Approximately 80% of breast cancers(BC) are estrogen receptor(ER)-positive and thus endocrine therapy(ET) should be considered complementary to surgery in the majority of patients. The advantages of oophorectomy, adrenalectomy and hypophysectomy in women with advanced BC have been demonstrated many years ago, and currently ET consist of(1) ovarian function suppression(OFS), usually obtained using gonadotropinreleasing hormone agonists(Gn RHa);(2) selective estrogen receptor modulators or down-regulators(SERMs or SERDs); and(3) aromatase inhibitors(AIs), or a combination of two or more drugs. For patients aged less than 50 years and ER+ BC, there is no conclusive evidence that the combination of OFS and SERMs(i.e., tamoxifen) or chemotherapy is superior to OFS alone. Tamoxifen users exhibit a reduced risk of BC, both invasive and in situ, especially during the first 5 years of therapy, and extending the treatment to 10 years further reduced the risk of recurrences. SERDs(i.e., fulvestrant) are especially useful in the neoadjuvant treatment of advanced BC, alone or in combination with either cytotoxic agents or AIs. There are two types of AIs: type Ⅰ are permanent steroidal inhibitors of aromatase, while type Ⅱ are reversible nonsteroidal inhibitors. Several studies demonstrated the superiority of the third-generation AIs(i.e., anastrozole and letrozole) compared with tamoxifen, and adjuvant therapy with AIs reduces the recurrence risk especially in patients with advanced BC. Unfortunately, some cancers are or became ET-resistant, and thus other drugs have been suggested in combination with SERMs or AIs, including cyclin-dependent kinase 4/6 inhibitors(palbociclib) and mammalian target of rapamycin(m TOR) inhibitors, such as everolimus. Further studies are required to confirm their real usefulness. | Franco Lumachi Davide A Santeufemia Stefano MM Basso | 2015 | World Journal of Biological Chemistry2015，6，3： | 16 |
| 2 | Expression of p53 and Ki-67 as prognostic factors for survival of men with colorectal cancer显示文摘 | Lumachi F Orlando R Marino F | 2012 | An- ticancer Res2012，32，9： | 1 |
| 3 | Arterial blood pressure,serum calcium and PTH in elderly men with parathyroid tumors and primary hyperparathyroidism显示文摘 | Lumachi F Camozzi V Luisetto G | | 0，，11： | 1 |
| 4 | Technetium-99m sestamibiscintigraphy and helical CT together in patients with primary hyperparathyroidism:a prospective clinical study显示文摘 | Lumachi F Tregnaghi A Zucchetta P | 2004 | Br J Radiol2004，77，914： | 1 |
| 5 | Pathophysiology and treatment of nonfamilial hyperparathyroidism 显示文摘 | Lumachi F Basso SM | 2014 | Recent Pat CNS Drug Discov2014，9，： | 1 |
| 6 | Estrogen therapy and risk of breast cancer in postmenopausal woman:a case- control study and results of a multivariate analysis 显示文摘 | Lumachi F Frigo AC Basso U | 2010 | MenoPause2010，17，3： | 1 |
| 7 | Relationship between serum parathyroid hormone,serum calcium and arterial blood pressure in patients with primary hyperparathyroidism:results of a multivariate analysis显示文摘 | Lumachi F Ermani M Luisetto G | | 0，，05： | 1 |
| 8 | Parathyroid cancer: etiology, clinical presentation and treatment显示文摘 | Lumachi F Basso SM Basso U | 2006 | Anticancer Res2006，26，6： | 1 |
| 9 | Usefulness of 99mTc ses- tamibi scintimammography in suspected breast cancer and in axil- lary lymph node metastases detection显示文摘 | Lumachi F Ferretti G Povolato M | 2001 | Eur Surg Oneol2001，27，： | 1 |
| 10 | Long-term results of adrenalectomy in patients with aldosterone-producing adenomas:multivariate analysis of factors affecting unresolved hypertension and review of the literature显示文摘 | LUMACHI F ERMANI M BASSO S M | | 0，，10： | 1 |
| 11 | Management of incidentally discovered adrenal masses and risk of malignancy显示文摘 | Lumachi F Basso S | 2002 | Surgery2002，128，6： | 1 |
| 12 | Usefullness of ultras-ound scissors in reducing serous drainage after axillary dissection for breast cancer a prospective randomized clini-cal study显示文摘 | Lumachi F Burelli P Basso SM | 2004 | Ame Surg2004，70，1： | 1 |
| 13 | 50P Accuracy of serum/ pleural fluid lactate dehydrogenase ratio measurement in patients with malignant pleural effusion显示文摘 | Lumachi F Tozzoli R Mazza F | 2016 | J Thoracic Oncol2016，11，4： | 1 |
| 14 | Sensitivity and positive predictive value of CT, MRI and ^123Ⅰ-MIBG scintig- raphy in llocalizing pheochromocytomas: a prospective study 显示文摘 | Lumachi F Tregnaghi A Zucchetta P | 2006 | Nucl Med Commun2006，27，： | 1 |
| 15 | Changes of bone formation markers osteocalcin and bone-specific alkaline phosphatase in postmenopausal women with osteoporosis 显示文摘 | Lumachi F Ermani M Camozzi V | 2009 | Ann N Y Acad Sci2009，10，7： | 1 |
| 16 | Sensitivity and positive predictive value of CT,MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas:aprospective study显示文摘 | Lumachi F Tregnaghi A Zucchetta P | | 0，，： | 1 |
| 17 | Seroma prevention following axiltary dissection in patients with breast cancer by using ultrasound scissors:a prospective clinical study 显示文摘 | Lumachi F Brandes AA Burelli P | 2004 | Eur J Surg Oncol2004，30，： | 1 |
| 18 | Cancer-induced hypercalcemia 显示文摘 | Lumachi F Brunello A Roma A | 2009 | Anticancer Res2009，29，5： | 1 |
| 19 | Treatment of acute hypercalcemia显示文摘 | Basso S M Lumachi F Nascimben F | 2012 | Med Chem2012，8，4： | 1 |
| 20 | Incidence of arm lymphoedema following sentinel node biopsy,axillary sampling and axillary dissection in patients with breast cancer显示文摘 | Lumachi F Basso SM Bonamini M | 2009 | In Vivo2009，23，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员